The Combined Utility of Angio-CT and MRI in Managing Chronic Musculoskeletal Pain: a Prospective Study to Evaluate the Efficacy of Transarterial Microembolization
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Transarterial microembolization (TAME).
- Who it may be relevant to
- Registry conditions: Chronic Musculoskeletal Disease, Transarterial Embolization, Magnetic Resonance Imaging, Angiography. Basic parameters: 20 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Taiwan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Transarterial microembolization (TAME) is a novel treatment option for chronic musculoskeletal pain, especially suitable for patients who have not responded to conservative treatment or are unsuitable for surgical procedures. This minimally invasive technique primarily targets abnormal neovascularization for embolization, relying heavily on precise information provided by various imaging techniques to ensure the effectiveness and safety of the treatment. This study aims to explore the application of integrating preoperative magnetic resonance imaging (MRI) evidence of patient pain and intraoperative high-resolution synchronous imaging information from fused computed tomography (CT) and angiography systems. This integration is intended to enhance preoperative planning, intraoperative guidance, and final treatment outcome assessment, focusing on its crucial contribution to treatment success. It is hoped that this approach will provide pain intervention physicians with reliable diagnostic tools and safe treatment methods, thereby improving treatment outcomes for patients with chronic musculoskeletal pain.
Interventions
- Procedure Transarterial microembolization (TAME)
TAME primarily targets abnormal neovascularization for embolization in chronic shoulder or knee joint pain.
Primary outcome measures
- Pain relief [Time frame: day 0, day 1, week 1, month 1, month 3, and month 6.]
Secondary outcome measures (2)
- Functional improvement (for shoulder joint) [Time frame: day 0, day 1, week 1, month 1, month 3, and month 6.]
- Functional improvement (for knee joint) [Time frame: day 0, day 1, week 1, month 1, month 3, and month 6.]
Eligibility criteria
Inclusion criteria
- Patients with chronic musculoskeletal shoulder or knee joint pain in our hospital, including degenerative knee arthritis, adhesive capsulitis of the shoulder, and those confirmed by physical examination or ultrasound-guided injection to have tendinopathy or ligamentopathy, who have failed drug therapy, rehabilitation, or injection treatments, with a duration of symptoms greater than three months, are the target population of this study.
Exclusion criteria
- Pregnancy, coagulation disorders, symptoms of relevant local infections or tumors, and patients allergic to contrast agents. Patients must have complete medical records; those who do not meet the inclusion criteria will be excluded.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Taiwan · 1 center
- Tri-Service General Hospital — Taipei
Publications
- Liao WC, Huang HY, Chen YH, Huang HB, Liaw WJ, Hsu YC. Nonselective Intra-arterial CT Angiography Versus Selective Digital Subtraction Angiography for Detecting Neovascularization During Transarterial Embolization for Adhesive Capsulitis. Cardiovasc Intervent Radiol. 2026 Jul 29. doi: 10.1007/s00270-026-04533-0. Online ahead of print. PMID 42527615
Identifiers
NCT: NCT06509087 · C202405040